TCC Wiki

Lysergic acid diethylamide

13pages on
this wiki
Add New Page
Talk0 Share


Lysergic acid diethylamide, LSD-25, LSD, formerly lysergide, commonly known as acid, is a semisynthetic psychedelic drug of the ergoline family. LSD is non-addictive, non-toxic, and is well known for its psychological effects which can include closed and open eye visuals, a sense of time distortion, ego death and profound cognitive shifts, as well as for its key role in 1960's counterculture.  It is used mainly by psychonauts as an entheogen and in psychedelic therapy.

LSD was first synthesized by Albert Hofmann in 1938 from ergot, a grain fungus that typically grows on rye. The short form LSD comes from its early code name LSD-25, which is an abbreviation for the German "Lysergsäure-diethylamid" followed by a sequential number.<ref name="problem-child">Hofmann, Albert. LSD—My Problem Child (McGraw-Hill, 1980). ISBN 0-07-029325-2.</ref><ref name="tihkal" />  LSD is sensitive to oxygen, ultraviolet light, and chlorine, especially in solution, though its potency may last for years if it is stored away from light and moisture at low temperature. In pure form it is a colourless, odourless, and mildly bitter solid.<ref>Template:Cite book</ref> LSD is typically delivered orally, usually on a substrate such as absorbent blotter paper, a sugar cube, or gelatin. In its liquid form, it can be administered by intramuscular or intravenous injection. The threshold dosage level needed to cause a psychoactive effect on humans is between 20 and 30 µg (micrograms).<ref name="greiner" />

Introduced by Sandoz Laboratories, with trade-name Delysid, as a drug with various psychiatric uses in 1947, LSD quickly became a therapeutic agent that appeared to show great promise. However, the emerging recreational use of the drug by youth culture in the Western world during the 1960s led to a political firestorm that resulted in its prohibition.<ref> Template:Cite web</ref> A number of organizations—including the Beckley Foundation, MAPS, Heffter Research Institute and the Albert Hofmann Foundation—exist to fund, encourage and coordinate research into its medicinal uses.<ref> Template:Cite web</ref>

== Dosage ==
File:10 strip.jpg

File:LSD Tabs.jpg

A single dose of LSD may be between 100 and 500 micrograms — an amount roughly equal to one-tenth the mass of a grain of sand.
Threshold effects can be felt with as little as 25 micrograms of LSD.<ref name="greiner">Template:Cite journal</ref>
<ref name="greiner" /><ref>Stoll, W.A. (1947). Ein neues, in sehr kleinen Mengen wirsames Phantastikum. Schweiz. Arch. Neur. 60,483.</ref> Dosages of LSD are measured in micrograms (µg), or millionths of a gram. By comparison, dosages of most drugs, both recreational and medicinal, are measured in milligrams (mg), or thousandths of a gram. For example, an active dose of mescaline, roughly 0.2 to 0.5g, has effects comparable to 100 µg or less of LSD.<ref name="problem-child" />

Typical doses in the 1960s ranged from 200 to 1000 µg while street samples of the 1970s contained 30 to 300 µg. By the 1980s, the amount had reduced to between 100 to 125 µg, lowering more in the 1990s to the 20–80 µg range.<ref name="henderson-glass">Template:Cite book</ref>

Estimates for the lethal dosage (LD<sub>50</sub>) of LSD range from between 200 µg/kg to more than 1 mg/kg of human body mass, though most sources report that there are no known human cases of such an overdose. Other sources note one report of a suspected fatal overdose of LSD occurring in November 1975 in Kentucky in which there were indications that ~1/3 of a gram (320 mg or 320,000 µg) had been injected intravenously. (This is a very extraordinary amount, particularly when compared to the average LSD dosage of ~100 µg)<ref name="erowid-dosage">Template:Cite web</ref><ref>Template:Cite web</ref> Experiments with LSD were also done on animals; in 1962, an elephant named Tusko died shortly after being injected with 297 mg, but whether the LSD was the cause of his death is controversial.<ref>{{cite web
| author     = Erowid & R. Stuart
| year       = 2002
| title      = LSD Related Death of an Elephant - Controversy surrounding the 1962 death of an elephant after an injection of LSD
| url        =
| publisher  = Erowid
| accessdate = 2008-07-28

== History ==
Main article: History of LSD
LSD was first synthesized on November 16, 1938<ref>Dr. Albert Hofmann; translated from the original German (LSD Ganz Persönlich) by J. Ott. MAPS-Volume 6 Number 69 Summer 1969</ref> by Swiss chemist Dr. Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. LSD's psychedelic properties were discovered 5 years later when Hofmann accidentally ingested an unknown quantity of the chemical.<ref name=hyponichols> Template:Cite web</ref> The first intentional ingestion of LSD occurred on April 19, 1943, when Dr. Hofmann ingested 250 µg of LSD. He hypothesized this would be a threshold dose based on the dosages of other ergot alkaloids. Hofmann found the effects to be much stronger than he anticipated.<ref name=histlsd> Template:Cite web</ref> Sandoz Laboratories introduced LSD as a psychiatric drug in 1947.<ref>LSD: The Drug</ref>

Beginning in the 1950s the US Central Intelligence Agency began a research program code named Project MKULTRA. Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public in order to study their reactions, usually without the subject's knowledge. The project was revealed in the US congressional Rockefeller Commission report in 1975.

In 1963 the Sandoz patents expired on LSD.<ref name="henderson-glass"/> Also in 1963, the US Food and Drug Administration classified LSD as an Investigational New Drug, which meant new restrictions on medical and scientific use.<ref name="henderson-glass"/> Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, began to advocate the use of LSD. LSD became central to the counterculture of the 1960s. On October 24, 1968, possession of LSD was banned in the United States.<ref>Template:Cite web</ref> The last FDA approved human study with LSD, for use in dying cancer patients, ended in 1980. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993.<ref>Template:Cite web</ref> Today, medical research is resuming around the world.<ref>MAPS Psychedelic Research</ref>

== Effects ==
=== Physical ===
[[File:Possible physical effects of lysergic acid diethylamide (LSD).svg|thumb|250px|Possible physical effects of LSD.<ref>Reference list is found in image page at File:Possible physical effects of lysergic acid diethylamide (LSD).png#References</ref>

Physical reactions to LSD are highly variable and nonspecific. The following symptoms have been reported: uterine contractions, hypothermia, fever, elevated levels of blood sugar, goose bumps, increase in heart rate, jaw clenching, perspiration, pupil-dilation, saliva production, mucus production, sleeplessness, hyperreflexia, and tremors. Some users report a strong metallic taste for the duration of the effects. LSD users have reported numbness, weakness and nausea.<ref>Template:Cite journal</ref>

LSD is not considered addictive by the medical community.<ref>Template:Cite journal</ref> Rapid tolerance build-up prevents regular use, and there is cross-tolerance shown between LSD, mescaline<ref name="isbell_mescaline">{{cite journal
| author = Wolbach AB Jr, Isbell H, Miner EJ
| title = Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions
| journal= Psychopharmacologia
| year= 1962
| volume = 3
| pages= 1–14
| url =
| pmid = 14007904
| doi = 10.1007/BF00413101
and psilocybin.<ref name="isbell_psilocybin">{{cite journal
| author = Isbell H, Wolbach AB, Wikler A, Miner EJ
| title = Cross Tolerance between LSD and Psilocybin
| journal= Psychopharmacologia
| year= 1961
| volume = 2
| page = E353
| url =
| pmid = 13717955
| doi = 10.1007/BF00407974
}}</ref> This tolerance diminishes after a few days without use and is probably caused by downregulation of 5-HT<sub>2A</sub> receptors in the brain<!-- PMID 2803482, PMID 1969270 -->.

=== Psychological ===

LSD's psychological effects (colloquially called a "trip") vary greatly from person to person, depending on factors such as previous experiences, state of mind and environment, as well as dose strength. They also vary from one trip to another, and even as time passes during a single trip. An LSD trip can have long-term psychoemotional effects; some users cite the LSD experience as causing significant changes in their personality and life perspective. Widely different effects emerge based on what has been called set and setting; the "set" being the general mindset of the user, and the "setting" being the physical and social environment in which the drug's effects are experienced.

Some psychological effects may include an experience of radiant colors, objects and surfaces appearing to ripple or "breathe," colored patterns behind the eyes, a sense of time distorting (time seems to be stretching, repeating itself, changing speed or stopping), crawling geometric patterns overlaying walls and other objects, morphing objects, a sense that one's thoughts are spiraling into themselves, loss of a sense of identity or the ego (known as "ego death"), and other powerful psycho-physical reactions.<ref>{{cite web
|author     = The Good Drugs Guide
|title      = LSD psychedelic effects
|url        =
|accessdate = 2008-03-03}}</ref> Many users experience a dissolution between themselves and the "outside world".<ref name="linton-langs">Linton, Harriet B. and Langs, Robert J. "Subjective Reactions to Lysergic Acid Diethylamide (LSD-25)". Arch. Gen. Psychiat. Vol. 6 (1962): 352–68.</ref> This unitive quality may play a role in the spiritual and religious aspects of LSD. The drug sometimes leads to disintegration or restructuring of the user's historical personality and creates a mental state that some users report allows them to have more choice regarding the nature of their own personality.

If the user is in a hostile or otherwise unsettling environment, or is not mentally prepared for the powerful distortions in perception and thought that the drug causes, effects are more likely to be unpleasant than if he or she is in a comfortable environment and has a relaxed, balanced and open mindset.<ref>{{cite web
|     title = LSD dangers
|       url =
| publisher = The Good Drugs Guide
|accessdate = 2008-10-20

==== Sensory / perception ====

LSD causes expansion and an altered experience of senses, emotions, memories, time, and awareness for 6 to 14 hours, depending on dosage and tolerance. Generally beginning within thirty to ninety minutes after ingestion, the user may experience anything from subtle changes in perception to overwhelming cognitive shifts. Changes in auditory and visual perception are typical.<ref name="linton-langs" /><ref>{{cite journal
| author=Katz MM, Waskow IE, Olsson J
| year=1968
| title=Characterizing the psychological state produced by LSD
| journal=J Abnorm Psychol
| volume=73
| issue=1
| pages=1–14
| pmid=5639999 | doi = 10.1037/h0020114
}}</ref> Visual effects include the illusion of movement of static surfaces ("walls breathing"), after image-like trails of moving objects ("tracers"), the appearance of moving colored geometric patterns (especially with closed eyes), an intensification of colors and brightness ("sparkling"), new textures on objects, blurred vision, and shape suggestibility. Users commonly report that the inanimate world appears to animate in an unexplained way; for instance, objects that are static in three dimensions can seem to be moving relative to one or more additional spatial dimensions.<ref>See, e.g., Gerald Oster's article "Moiré patterns and visual hallucinations". Psychedelic Rev. No. 7 (1966): 33–40.</ref> Many of the basic visual effects resemble the phosphenes seen after applying pressure to the eye and have also been studied under the name "form constants". The auditory effects of LSD may include echo-like distortions of sounds, changes in ability to discern concurrent auditory stimuli, and a general intensification of the experience of music. Higher doses often cause intense and fundamental distortions of sensory perception such as synaesthesia, the experience of additional spatial or temporal dimensions, and temporary dissociation.

==Potential use==
LSD has been used in in psychiatry for its perceived therapeutic value, in the treatment of alcoholism, pain and cluster headache relief, for spiritual purposes, and to enhance creativity. However, government organizations like the United States Drug Enforcement Administration maintain that LSD "produces no aphrodisiac effects, does not increase creativity, has no lasting positive effect in treating alcoholics or criminals, does not produce a 'model psychosis', and does not generate immediate personality change."<ref>DEA - Publications - LSD in the US - The Drug<!-- Bot generated title --></ref></blockquote>

=== Psychotherapy ===
In the 1950s and 1960s LSD was used in psychiatry to enhance psychotherapy. Some psychiatrists believed LSD was especially useful at helping patients to "unblock" repressed subconscious material through other psychotherapeutic methods,<ref>Cohen, S. (1959). The therapeutic potential of LSD-25. A Pharmacologic Approach to the Study of the Mind, p251–258.</ref> and also for treating alcoholism. One study concluded, "The root of the therapeutic value of the LSD experience is its potential for producing self-acceptance and self-surrender,"<ref>Template:Cite journal</ref> presumably by forcing the user to face issues and problems in that individual's psyche.

In December 1968, a survey was made of all 74 UK doctors who had used LSD in humans, 73 replied, 1 had moved overseas and was unavailable. Of the 73 replies, the majority of UK doctors with clinical experience with LSD felt that LSD was effective and had acceptable safety: 41 (56%) continued with clinical use of LSD, 11 (15%) had stopped because of retirement or other extraneous reasons, 9 (12%) had stopped because they found LSD ineffective, and 5 (7%) had stopped because they felt LSD was too dangerous.<ref name="Malleson 1971" />

=== Alcoholism ===
Some studies in the 1950s that used LSD to treat alcoholism professed a 50% success rate,<ref>Maclean, J.R.; Macdonald, D.C.; Ogden, F.; Wilby, E., "LSD-25 and mescaline as therapeutic adjuvants." In: Abramson, H., Ed., The Use of LSD in Psychotherapy and Alcoholism, Bobbs-Merrill: New York, 1967, pp. 407–426; Ditman, K.S.; Bailey, J.J., "Evaluating LSD as a psychotherapeutic agent," pp.74–80; Hoffer, A., "A program for the treatment of alcoholism: LSD, malvaria, and nicotinic acid," pp. 353–402.</ref> five times higher than estimates near 10% for Alcoholics Anonymous.<ref>Template:Cite journal</ref>  These studies were criticized for methodological flaws, and different groups had inconsistent results. Mangini's 1998 paper reviewed this history. She concluded that the efficacy of LSD in treating alcoholism remains an open question.<ref>Template:Cite journal</ref>

=== Pain ===
LSD was studied in the 1960s by Eric Kast as an analgesic for serious and chronic pain caused by cancer or other major trauma.<ref>Template:Cite journal</ref> Even at low (sub-psychedelic) dosages, it was found to be at least as effective as traditional opiates, while being much longer lasting pain reduction (lasting as long as a week after peak effects had subsided). Kast attributed this effect to a decrease in anxiety. This reported effect is being tested (though not using LSD) in an ongoing (as of 2006) study of the effects of the psychedelic tryptamine psilocybin on anxiety in terminal cancer patients.

=== Cluster headaches ===
LSD has been used as a treatment for cluster headaches, an uncommon but extremely painful disorder. Researcher Peter Goadsby describes the headaches as "worse than natural childbirth or even amputation without anesthetic."<ref>Dr. Goadsby is quoted in "Research into psilocybin and LSD as cluster headache treatment", and he makes an equivalent statement in an Health Report interview on Australian Radio National (August 9, 1999). Pages accessed 2007-01-31.</ref> Although the phenomenon has not been formally investigated, case reports indicate that LSD and psilocybin can reduce cluster pain and also interrupt the cluster-headache cycle, preventing future headaches from occurring. Currently existing treatments include various ergolines, among other chemicals, so LSD's efficacy may not be surprising. A dose-response study testing the effectiveness of both LSD and psilocybin was planned at McLean Hospital, although the current status of this project is unclear. A 2006 study by McLean researchers interviewed 53 cluster-headache sufferers who treated themselves with either LSD or psilocybin, finding that a majority of the users of either drug reported beneficial effects.<ref name="sewell-etal2006">Template:Cite journal</ref> Unlike use of LSD or MDMA in psychotherapy, this research involves non-psychological effects and often sub-psychedelic dosages.<ref>Summarized from "Research into psilocybin and LSD as cluster headache treatment" and the Clusterbusters website. Pages accessed 2007-01-31.</ref>

=== Spiritual ===
LSD is considered an entheogen because it can catalyze intense spiritual experiences, during which users may feel they have come into contact with a greater spiritual or cosmic order. Users claim to experience lucid sensations where they have "out of body" experiences. Some users report insights into the way the mind works, and some experience long-lasting changes in their life perspective. Some users consider LSD a religious sacrament, or a powerful tool for access to the divine. Dr. Stanislav Grof has written that religious and mystical experiences observed during LSD sessions appear to be phenomenologically indistinguishable from similar descriptions in the sacred scriptures of the great religions of the world and the secret mystical texts of ancient civilizations.<ref name="Grof1979">Template:Cite book</ref>
<!--This example is not of LSD use, but of psilocybin use.

Such experiences under the influence of LSD have been observed and documented by researchers such as Timothy Leary and Stanislav Grof.<ref name="sgrof"/>For example, Walter Pahnke conducted the Good Friday Marsh Chapel Experiment in 1962 under Leary's supervision, performing a double blind experiment on the administration of psilocybin to volunteers who were students in religious graduate programs, e.g., divinity or theology.<ref>Video of the experiment can be viewed here.</ref> That study provided evidence that psychotropics may induce mystical religious states.<ref>Pahnke, Walter N., Drugs and Mysticism: An Analysis of the Relationship between Psychedelic Drugs and the Mystical Consciousness. A thesis presented to the Committee on Higher Degrees in History and Philosophy of Religion, Harvard University, June 1963. Cited in Masters, R.E.L., & Houston, Jean., The Varieties of Psychedelic Experience (Turnstone Books, 1973).</ref>-->

===Creativity ===
In the 1950s and 1960s, psychiatrists like Oscar Janiger explored the potential effect of LSD on creativity.  Experimental studies attempted to measure the effect of LSD on creative activity and aesthetic appreciation.<ref name="PMID18562421">Template:Cite journal</ref><ref name="PMID2723891">Template:Cite journal</ref><ref name="Stafford-Golightly">Template:Cite book</ref><ref name="PMID6054248">Template:Cite journal</ref>

== Dangers ==

LSD is generally considered nontoxic, although it may temporarily impair the ability to make sensible judgments and understand common dangers, thus making the user more susceptible to accidents and personal injury.

=== Adverse Drug Interactions ===
There is some indication that LSD may trigger a dissociative fugue state in individuals who are taking certain classes of antidepressants such as lithium salts and tricyclics. In such a state, the user has an impulse to wander, and may not be aware of his or her actions, which can lead to physical injury. Anonymous anecdotal reports have attributed seizures and one death to the combination of LSD with lithium.<ref name="lsd-antidepressants">"LSD and Antidepressants" (2003) via Erowid.</ref> SSRIs are believed to interact more benignly, with a tendency to noticeably reduce LSD's subjective effects.<ref>Kit Bonson, "The Interactions between Hallucinogens and Antidepressants" (2006).</ref> Similar and perhaps greater effects have also been reported with MAOIs.<ref name="lsd-antidepressants" />

=== Uterine contractions ===
As Albert Hofmann reports in LSD – My Problem Child, the early pharmacological testing Sandoz performed on the compound (before he ever discovered its psychoactive properties) indicated that LSD has a pronounced effect upon the mammalian uterus. Sandoz's testing showed that LSD can stimulate uterine contractions with efficacy comparable to ergobasine, the active uterotonic component of the ergot fungus (Hofmann's work on ergot derivatives also produced a modified form of ergobasine which became a widely accepted medication used in obstetrics, under the trade name Methergine). Therefore, LSD use by pregnant women could be dangerous and is contraindicated.<ref name="problem-child" />

=== Genetic ===
Initial studies in the 1960s and 1970s raised concerns that LSD might produce genetic damage<ref name="dishotsky">Template:Cite journal</ref> or developmental abnormalities in fetuses. However, these initial reports were based on in vitro studies or were poorly controlled and have not been substantiated. In studies of chromosomal changes in human users and in monkeys, the balance of evidence suggests no increase in chromosomal damage. For example, studies were conducted with people who had been given LSD in a clinical setting.<ref name="dishotsky"/> White blood cells from these people were examined for visible chromosomal abnormalities. Overall, there appeared to be no lasting changes. Several studies have been conducted using illicit LSD users and provide a less clear picture. Interpretation of this data is generally complicated by factors such as the unknown chemical composition of street LSD, concurrent use of other psychoactive drugs, and diseases such as hepatitis in the sampled populations. It seems possible that the small number of genetic abnormalities reported in users of street LSD is either coincidental or related to factors other than a toxic effect of pure LSD.<ref name="dishotsky" />

=== Flashbacks versus HPPD ===
Template:See also
"Flashbacks" are a reported psychological phenomenon in which an individual experiences an episode of some of LSD's subjective effects long after the drug has worn off — usually in the days after typical doses. In some rarer cases, flashbacks have lasted longer, but are generally short-lived and mild compared to the actual LSD "trip."  Flashbacks can incorporate both positive and negative aspects of LSD trips.  Flashbacks have proven difficult to study and are no longer officially recognized as a psychiatric syndrome.  However, colloquial usage of the term persists and usually refers to any drug-free experience reminiscent of psychedelic drug effects, with the typical connotation that the episodes are of short duration.

No definitive explanation is currently available for these experiences. Any attempt at explanation must reflect several observations: first, over 70 percent of LSD users claim never to have "flashed back"; second, the phenomenon does appear linked with LSD use, though a causal connection has not been established; and third, a higher proportion of psychiatric patients report flashbacks than other users.<ref name="abrahart">{{cite web
| url =
| title = A Critical Review of Theories and Research Concerning Lysergic Acid Diethylamide (LSD) and Mental Health
| author = David Abrahart
| accessdate = 2007-02-02}}</ref> Several studies have tried to determine how likely a user of LSD, not suffering from known psychiatric conditions, is to experience flashbacks. The larger studies include Blumenfeld's in 1971<ref>Template:Cite journal</ref> and Naditch and Fenwick's in 1977,<ref>Template:Cite journal</ref> which arrived at figures of 20% and 28%, respectively.

Although flashbacks themselves are not recognized as a medical syndrome, there is a recognized syndrome called Hallucinogen Persisting Perception Disorder (HPPD) in which LSD-like visual changes are not temporary and brief, as they are in flash-backs, but instead are persistent, and cause clinically significant impairment or distress. The syndrome is a DSM-IV diagnosis. Several scientific journal articles have described the disorder.<ref>See, for example, Template:Cite journal</ref>

HPPD differs from flashbacks in that it is persistent and apparently entirely visual (although mood and anxiety disorders are sometimes diagnosed in the same individuals). A recent review suggests that HPPD (as defined in the DSM-IV) is rare and affects only a distinctly vulnerable subpopulation of users.<ref>Template:Cite journal; Template:Cite journal [1]</ref>  However, it is possible that the prevalence of HPPD is underestimated because most of the diagnoses are applied to people who are willing to admit to their health care practitioner that they have previously used psychotropics, and presumably many people are reluctant to admit this.<ref>Template:Cite web</ref>

There is no consensus regarding the nature and causes of HPPD (or flashbacks).  A study of 44 HPPD subjects who had previously ingested LSD showed EEG abnormalities.<ref>Template:Cite journal</ref> Given that some symptoms have environmental triggers, it may represent a failure to adjust visual processing to changing environmental conditions.  There are no explanations for why only some individuals develop HPPD.  Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence.<ref name="abrahart" /> Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of HPPD appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder. Instead, some cases appear to involve only visual symptoms.<ref name="abrahart" />

=== Psychosis ===
There are some cases of LSD inducing a psychosis in people who appeared to be healthy prior to taking LSD. This issue was reviewed extensively in a 1984 publication by Rick Strassman.<ref>Template:Cite journal</ref> In most cases, the psychosis-like reaction is of short duration, but in other cases it may be chronic. It is difficult to determine whether LSD itself induces these reactions or if it triggers latent conditions that would have manifested themselves otherwise. The similarities of time course and outcomes between putatively LSD-precipitated and other psychoses suggests that the two types of syndromes are not different and that LSD may have been a nonspecific trigger.

Estimates of the prevalence of LSD-induced prolonged psychosis lasting over 48 hours have been made by surveying researchers and therapists who had administered LSD:
* Cohen (1960) estimated 0.8 per 1,000 volunteers (the single case among approx. 1250 study volunteers was the identical twin of a schizophrenic and he recovered within 5 days) and 1.8 per 1,000 psychiatric patients (7 cases among approx. 3850 patients, of which 2 cases were "preschizophrenic" or had previous hallucinatory experience, 1 case had unknown outcome, 1 case had incomplete recovery, and 5 cases recovered within up to 6 months).<ref name="Cohen 1960">Template:Cite journal</ref>
* Malleson (1971) reported no cases of psychosis among experimental subjects (170 volunteers who received a total of 450 LSD sessions) and estimated 9 per 1,000 in psychiatric patients (37 cases among 4300 patients, of which 8 details are unknown, 10 appeared chronic, and 19 recovered completely within up to 3 months).<ref name="Malleson 1971">Template:Cite journal</ref>.

However, in neither survey study was it possible to compare the rate of lasting psychosis in these volunteers and patients receiving LSD with the rate of psychosis found in other groups of research volunteers or in other methods of psychiatric treatment (for example, those receiving placebo).

Cohen (1960) noted:<ref name="Cohen 1960" />
:"The hallucinogenic experience is so striking that many subsequent disturbances may be attributed to it without further justification. The highly suggestible or hysterical individual would tend to focus on his LSD experience to explain subsequent illness. Patients have complained to Abramson that their LSD exposure produced migraine headaches and attacks of influenza up to a year later. One Chinese girl became paraplegic and ascribed that catastrophe to LSD. It so happened that these people were all in the control group and had received nothing but tap water."

=== "Antidotes" ===
Adverse effects of psychotropics are often treated with fast-acting benzodiazepines like diazepam or triazolam that have calming and antianxiety effects but do not directly affect the specific actions of psychotropics. Many rumors about home remedies to counteract psychedelic effects are circulated, including orange juice, vanilla essence, vitamin C, and anti-histamines. These may have a placebo effect, working by making the taker think they have done something to make it better.<ref>{{cite web
| author     = RaveSafe
| year       = 1999
| title      = RaveSafe Q&A - Can you actually end an acid trip?
| url        =  
| accessdate = 2008-07-28
}}</ref> Theoretically, specific 5-HT<sub>2A</sub> receptor antagonists, such as Seroquel, would be direct antidotes, although some anecdotal reports claim otherwise.<ref>Huxley, Aldous The Doors of Perception and Heaven & Hell, Harper & Row, 1954.</ref> Also, some people have reported that taking an SSRI such as Prozac or drugs that are 5-HT<sub>2</sub> receptor antagonists such as Trazodone will counteract the effects of LSD.<ref>{{cite web
| author     = Bonson, Kit
| year       = 1994
| title      = The Interactions between Hallucinogens and Antidepressants - Summary of Results from Online Survey and Online Interviews
| url        =
| publisher  = Erowid
| accessdate = 2008-07-28
}}</ref> Some reports indicate that although administration of chlorpromazine (Thorazine) or similar typical antipsychotic tranquilizers will not end an LSD trip, it will either lessen the intensity or immobilize and numb the patient, a side effect of the medication.<ref>Template:Cite journal</ref> While it also may not end an LSD trip, the best chemical treatment for a "bad trip" is an anxiolytic agent such as diazepam (Valium) or another benzodiazepine. As the effect of the drug is psychological as well as physical, any treatment should focus on calming the patient. Limiting stimuli such as bright lights and loud noises can help in the event of an ill reaction.

== Pharmacokinetics ==
LSD's effects normally last from 6–12 hours depending on dosage, tolerance, body weight and age<ref name="tihkal">Alexander and Ann Shulgin. "LSD", in TiHKAL (Berkeley: Transform Press, 1997). ISBN 0-963-00969-9.</ref> - Sandoz's prospectus for "Delysid" warned: "intermittent disturbances of affect may occasionally persist for several days."<ref name="problem-child" /> Contrary to early reports and common belief, LSD effects do not last longer than the amount of time significant levels of the drug are present in the blood. Aghajanian and Bing found LSD had an elimination half-life of 175 minutes,<ref name="Aghajanian" /> while, more recently, Papac and Foltz reported that 1 µg/kg oral LSD given to a single male volunteer had an apparent plasma half-life of 5.1 hours, with a peak plasma concentration of 5 ng/mL at 3 hours post-dose.<ref name="Papac" />

== Pharmacodynamics ==
[[Image:LSDaffinities.GIF|thumb|300px|Affinity of LSD for various receptors, averaged from data from the K<sub>i</sub> Database]]

LSD affects a large number of the G protein coupled receptors, including all dopamine receptor subtypes, and all adrenoreceptor subtypes, as well as many others. LSD binds to most serotonin receptor subtypes except for 5-HT<sub>3</sub> and 5-HT<sub>4</sub>. However, most of these receptors are affected at too low affinity to be sufficiently activated by the brain concentration of approximately 10–20 nM.<ref name="nichols">Template:Cite journal</ref> In humans, recreational doses of LSD can affect 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>5A</sub>, and 5-HT<sub>6</sub> receptors.<ref name="Aghajanian" /><ref>{{cite web
| url=
| accessdate=2009-11-02
| title=PDSP database}}</ref>  5-HT<sub>5B</sub> receptors, which are not present in humans, also have a high affinity for LSD.<ref>{{cite journal
| author = Nelson, DL
| title = 5-HT5 receptors
| journal= Current drug targets. CNS and neurological disorders
| year = 2004
| month = February
| volume = 3
| issue = 1
| pages = 53–8
| pmid = 14965244}}</ref>  The psychedelic effects of LSD are attributed to its strong partial agonist effects at 5-HT<sub>2A</sub> receptors as specific 5-HT<sub>2A</sub> agonists are psychedelics and largely 5-HT<sub>2A</sub> specific antagonists block the psychedelic activity of LSD.<ref name="nichols" /> Exactly how this produces the drug's effects is unknown, but it is thought that it works by increasing glutamate release in the cerebral cortex and therefore excitation in this area, specifically in layers IV and V.<ref>BilZ0r. "The Neuropharmacology of Hallucinogens: a technical overview". Erowid, v3.1 (August 2005).</ref> In the later stages, LSD might act through DARPP-32-related pathways that are likely the same for multiple drugs including cocaine, methamphetamine, nicotine, caffeine, PCP, ethanol and morphine.<ref>{{cite journal
| author = Svenningsson P. , Nairn A. C., Greengard P.
| title = DARPP-32 Mediates the Actions of Multiple Drugs of Abuse.
| journal= AAPS Journal
| year= 2005
| volume = 07
| issue = 02
| pages= E353–E360
| doi = 10.1208/aapsj070235
| url =

== Chemistry ==
File:LSD isomers.png


LSD is an ergoline derivative. It is commonly synthesised by reacting diethylamine with an activated form of lysergic acid. Activating reagents include phosphoryl chloride<ref name="synth1">Template:Cite journal</ref> and peptide coupling reagents.<ref name="synth2">Template:Cite journal</ref> Lysergic acid is made by alkaline hydrolysis of lysergamides like ergotamine, a substance derived from the ergot fungus on rye, or from ergine (lysergic acid amide, LSA), a compound that is found in morning glory (Ipomoea tricolor) and hawaiian baby woodrose (Argyreia nervosa) seeds. Synthesizing LSD from LSA extracted from morning glory seeds is theoretically possible, but impractical and uncommon. Most chemists recommend ergot instead.<ref></ref> LSD is a chiral compound with two stereocenters at the carbon atoms C-5 and C-8, so that theoretically four different optical isomers of LSD could exist. LSD, also called (+)-<small>D</small>-LSD, has the absolute configuration (5R,8R). The C-5 isomers of lysergamides do not exist in nature and are not formed during the synthesis from <small>D</small>-lysergic acid. However, LSD and iso-LSD, the two C-8 isomers, rapidly interconvert in the presence of base. Non-psychoactive iso-LSD which has formed during the synthesis can be removed by chromatography and can be isomerized to LSD. A totally pure salt of LSD will emit small flashes of white light when shaken in the dark.<ref name="tihkal" /> LSD is strongly fluorescent and will glow bluish-white under UV light.

=== Stability ===

"LSD," writes the chemist Alexander Shulgin, "is an unusually fragile molecule."<ref name="tihkal" /> It is stable for indefinite time if stored as a solid salt or dissolved in water, at low temperature and protected from air and light exposure. Two portions of its molecular structure are particularly sensitive: the carboxamide attachment at the 8-position and the double bond between the 8-position and the aromatic ring. The former is affected by high pH, and if perturbed will produce isolysergic acid diethylamide (iso-LSD), which is biologically inactive. If water or alcohol adds to the double bond (especially in the presence of light), LSD converts to "lumi-LSD", which is totally inactive in human beings, to the best of current knowledge. Furthermore, chlorine destroys LSD molecules on contact; even though chlorinated tap water typically contains only a slight amount of chlorine, because a typical LSD solution only contains a small amount of LSD, dissolving LSD in tap water is likely to completely eliminate the substance.<ref name="tihkal" />

A controlled study was undertaken to determine the stability of LSD in pooled urine samples.<ref>Template:Cite journal</ref>
The concentrations of LSD in urine samples were followed over time at various temperatures, in different types of storage containers, at various exposures to different wavelengths of light, and at varying pH values. These studies demonstrated no significant loss in LSD concentration at 25 °C for up to four weeks. After four weeks of incubation, a 30% loss in LSD concentration at 37 °C and up to a 40% at 45 °C were observed. Urine fortified with LSD and stored in amber glass or nontransparent polyethylene containers showed no change in concentration under any light conditions. Stability of LSD in transparent containers under light was dependent on the distance between the light source and the samples, the wavelength of light, exposure time, and the intensity of light. After prolonged exposure to heat in alkaline pH conditions, 10 to 15% of the parent LSD epimerized to iso-LSD. Under acidic conditions, less than 5% of the LSD was converted to iso-LSD. It was also demonstrated that trace amounts of metal ions in buffer or urine could catalyze the decomposition of LSD and that this process can be avoided by the addition of EDTA.

== Production ==

Because an active dose of LSD is very minute, a large number of doses can be synthesized from a comparatively small amount of raw material. Beginning with ergotamine tartrate, for example, one can manufacture roughly one kilogram of pure, crystalline LSD from five kilograms of the ergotamine salt. Five kilograms of LSD — 25 kilograms of ergotamine tartrate — could provide 100 million doses, according to the DEA, more than enough to meet what is believed to be the entire annual U.S. demand. Since the masses involved are so small, concealing and transporting illicit LSD is much easier than smuggling other illegal drugs like cocaine or cannabis.<ref name="DEA-pub">{{cite web
|author      = DEA
|year        = 2007
|title       = LSD Manufacture - Illegal LSD Production
|url         =
|work        = LSD in the United States
|publisher   = U.S. Department of Justice Drug Enforcement Administration
|archiveurl  =
|archivedate = 2007-08-29

Manufacturing LSD requires laboratory equipment and experience in the field of organic chemistry. It takes two to three days to produce 30 to 100 grams of pure compound. It is believed that LSD is not usually produced in large quantities, but rather in a series of small batches. This technique minimizes the loss of precursor chemicals in case a step does not work as expected.<ref name="DEA-pub" />

=== Forms of LSD ===

LSD is produced in crystalline form and then mixed with excipients or redissolved for production in ingestible forms. Liquid solution is either distributed in small vials or, more commonly, sprayed onto or soaked into a distribution medium. Historically, LSD solutions were first sold on sugar cubes, but practical considerations forced a change to tablet form. Appearing in 1968 as an orange tablet measuring about 6 mm across "Sunshine" acid was the first largely available form of LSD after its possession was made illegal. Tim Scully, a prominent chemist, made some of it, but said that most "Sunshine" in the USA came by way of Ronald Stark, who imported approximately thirty-five million doses from Europe.<ref name=Stafford1992>{{
cite book
|last       = Stafford
|first      = Peter
|year       = 1992
|title      = Psychedelics Encyclopaedia
|chapter    = Chapter 1 - The LSD Family
|page      = 62
|edition    = Third Expanded Edition
|publisher  = Ronin Publishing Inc
|isbn       = 0-914171-51-8

Over a period of time, tablet dimensions, weight, shape and concentration of LSD evolved from large (4.5-8.1 mm diameter), heavyweight (≥150 mg), round, high concentration (90-350 µg/tab) dosage units to small (2.0-3.5 mm diameter) lightweight (as low as 4.7 mg/tab), variously shaped, lower concentration (12-85 µg/tab, average range 30-40 µg/tab) dosage units. LSD tablet shapes have included cylinders, cones, stars, spacecraft and heart shapes. The smallest tablets became known as "Microdots".<ref name=Laing2003>{{
cite book
|last       = Laing
|first      = Richard R.
|coauthors  = Barry L. Beyerstein, Jay A. Siegel
|year       = 2003
|title      = Hallucinogens: A Forensic Drug Handbook
|chapter    = Chapter 2.2 - Forms of the Drug
|chapterurl =,M1
|pages      = 39-41
|publisher  = Academic Press
|isbn       = 0124339514

After tablets came "computer acid" or "blotter paper LSD," typically made by dipping a preprinted sheet of blotting paper into an LSD/water/alcohol solution.<ref name=Stafford1992/><ref name=Laing2003/> More than 200 types of LSD tablets have been encountered since 1969 and more than 350 blotter paper designs have been observed since 1975.<ref name=Laing2003/> About the same time as blotter paper LSD came "Windowpane" (aka "Clearlight"), which contained LSD inside a thin gelatin square a quarter of an inch across.<ref name=Stafford1992/> <!-- Please do not add any street names here unless you can provide evidence for their notability and importance! Additions not referenced to a reliable source will be removed immediately. The goal of an encyclopedia is to provide a "ready reference" of key concepts, not give an exhaustive list of every detail.--> LSD has been sold under a wide variety of often short-lived and regionally restricted street names including Acid, Trips, Uncle Sid, Blotter, Lucy, and doses, as well as names that reflect the designs on the sheets of blotter paper.<ref name="erowid-faq">Honig, David. Frequently Asked Questions via Erowid</ref><ref>{{cite web
| url =
| title = Street Terms: Drugs and the Drug Trade
| publisher = Office of National Drug Control Policy
| date = 2005-04-05
| accessdate = 2007-01-31
}}</ref> Authorities have encountered the drug in other forms — including powder or crystal, and capsule.<ref>{{cite web
| author     = DEA
| year       = 2008
| title      = Photo Library (page 2)
| url        =
| publisher  = US Drug Enforcement Administration
| accessdate = 2008-06-27

=== Modern distribution ===
Template:Section OR
LSD manufacturers and traffickers in the United States can be categorized into two groups: A few large-scale producers, and an equally limited number of small, clandestine chemists, consisting of independent producers who, operating on a comparatively limited scale, can be found throughout the country. As a group, independent producers are of less concern to the Drug Enforcement Administration than the larger groups, as their product reaches only local markets.

=== LSD Mimics ===

In recent years, law enforcement in the United States and elsewhere has seized several chemicals and combinations of chemicals in blotter paper which were sold as LSD mimics, including DOB<ref name="microgram october 2005">
| journal=Microgram Bulletin
| date=October 2005
| year=2005
| author=United States Drug Enforcement Administration
| volume=38
| issue=10
| url=
| accessdate=2009-08-20}}</ref><ref name="microgram november 2006">
| journal=Microgram Bulletin
| date=November 2006
| year=2006
| volume=39
| issue=11
| author=United States Drug Enforcement Administration
| url=
| accessdate=2009-08-20}}</ref>, 2C-I<ref name="microgram february 2007">
| journal=Microgram Bulletin
| date=February 2007
| year=2007
| volume=40
| issue=2
| author=United States Drug Enforcement Administration
| url=
| accessdate=2009-08-20}}</ref><ref name="microgram december 2007">
| journal=Microgram Bulletin
| date=December 2007
| year=2007
| volume=40
| issue=12
| author=United States Drug Enforcement Administration
| url=
| accessdate=2009-08-20}}</ref>, DOC<ref name="microgram december 2007" />, a mixture of DOC and DOI<ref name ="microgram march 2008">
| journal=Microgram Bulletin
| date=March 2008
| year=2008
| volume=41
| issue=3
| author=United States Drug Enforcement Administration
| url=
| accessdate=2009-08-20}}</ref>, and a mixture of DOC and DOB<ref name="microgram march 2009">
| journal=Microgram Bulletin
| date=March 2009
| year=2009
| volume=42
| issue=3
| author=United States Drug Enforcement Administration
| url=
| accessdate=2009-08-20}}</ref>. Street users of LSD are often under the impression that blotter paper which is actively hallucinogenic can only be LSD because that is the only chemical with low enough doses to fit on a small square of blotter paper. While it is true that LSD requires lower doses than most other hallucinogens, blotter paper is capable of absorbing a much larger amount of material. The DEA performed a chromatographic analysis of blotter paper containing 2C-C which showed that the paper contained a much greater concentration of the active chemical than typical LSD doses, although the exact quantity was not determined.<ref name="microgram november 2005">
| journal=Microgram Bulletin
| date=November 2005
| year=2005
| volume=38
| issue=11
| author=United States Drug Enforcement Administration
| url=
| accessdate=2009-08-20}}</ref> Blotter LSD mimics can have relatively small dose squares; a sample of blotter paper containing DOC seized by Concord, California police had dose markings approximately 6 mm apart.<ref name="microgram december 2007" />

== Legal status ==
The United Nations Convention on Psychotropic Substances (adopted in 1971) requires its parties to prohibit LSD. Hence, it is illegal in all parties to the convention, which includes the United States, Australia, New Zealand, and most of Europe. However, enforcement of extant laws varies from country to country. Medical and scientific research with LSD in humans is permitted under the 1971 UN Convention.

=== Canada ===
In Canada, LSD is a controlled substance under Schedule III of the Controlled Drugs and Substances Act.<ref name="cdasa">{{cite web
| url = Drugs and Substances Act
| accessdate=2007-07-05
| publisher=Canadian Department of Justice
| year=1996
| author=Canadian government
| work=Justice Laws}}</ref> Every person who seeks to obtain the substance, without disclosing authorization to obtain such substances 30 days prior to obtaining another prescription from a practitioner, is guilty of an indictable offense and liable to imprisonment for a term not exceeding 3 years. Possession for purpose of trafficking is an indictable offense punishable by imprisonment for 10 years.

=== Hong Kong ===
In Hong Kong, Lysergide and derivatives are regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance, and can be used legally only by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without prescription can be fined HK$10,000. The maximum penalty for trafficking or illegally manufacturing the substance is a HK$5,000,000 fine and life imprisonment. Possession of the substance for consumption without license from the Department of Health is illegal with a HK$1,000,000 fine and/or seven years' imprisonment.

=== United Kingdom ===
In the United Kingdom, LSD is a class A drug. This means that possession of the drug without a license is punishable with 7 years imprisonment and/or an unlimited fine, and trafficking is punishable with life imprisonment and an unlimited fine (see main article on drug punishments Misuse of Drugs Act 1971).

In 2000, after consultation with members of the Royal College of Psychiatrists' Faculty of Substance Misuse, the UK Police Foundation issued the Runciman Report which recommended "the transfer of LSD from Class A to Class B".<ref>Drugs and the law: Report of the inquiry into the Misuse of Drugs Act 1971 London: Police Foundation, 2000, Runciman Report</ref>

In Nov 2009, the UK Transform Drug Policy Foundation released in the House of Commons a guidebooks to the legal regulation of drugs, After the War on Drugs: Blueprint for Regulation, which details options for regulated distribution and sale of LSD and other psychedelics.<ref>After the War on Drugs: Blueprint for Regulation Transform Drug Policy Foundation 2009</ref>

=== United States ===
LSD is Schedule I in the United States, according to the Controlled Substances Act of 1970.<ref>From [2]: LSD is a Schedule I substance under the Controlled Substances Act.</ref> This means LSD is illegal to manufacture, buy, possess, process, or distribute without a DEA license. By classifying LSD as a Schedule I substance, the Drug Enforcement Administration holds that LSD meets the following three criteria: it is deemed to have a high potential for abuse; it has no legitimate medical use in treatment; and there is a lack of accepted safety for its use under medical supervision. LSD prohibition does not make an exception for religious use. Note, there are very few or no documented deaths due to chemical toxicity, most LSD deaths are a result of behavioral toxicity.

There can also be substantial discrepancies between the amount of chemical LSD that one possesses and the amount of possession with which one can be charged in the U.S. This is because LSD is almost always present in a medium (e.g. blotter or neutral liquid), and the amount that can be considered with respect to sentencing is the total mass of the drug and its medium. This discrepancy was the subject of 1995 United States Supreme Court case, Neal v. U.S.<ref>{{cite court
| litigants=Neal v. United States
| reporter=U.S.
| volume=516
| opinion=284
| pinpoint=
| court=
| url=
}}, originating from U.S. v. Neal, 46 F.3d 1405 (7th Cir. 1995)</ref>

Lysergic acid and lysergic acid amide, LSD precursors, are both classified in Schedule III of the Controlled Substances Act. Ergotamine tartrate, a precursor to lysergic acid, is regulated under the Chemical Diversion and Trafficking Act.

Prior to October 6, 1966, LSD was available legally in the United States as an experimental psychiatric drug. Black market LSD has been manufactured in the US since the 1960s. Historically, LSD was distributed not for profit, but because those who made and distributed it truly believed that the psychedelic experience could do good for humanity, that it expanded the mind and could bring understanding and love. A limited number of chemists, probably fewer than a dozen, are believed to have manufactured nearly all of the illicit LSD available in the United States. The best known of these is undoubtedly Augustus Owsley Stanley III, usually known simply as Owsley.

American LSD usage declined in the 1970s and 1980s, then experienced a mild resurgence in popularity in the 1990s. Although there were many distribution channels during this decade, the U.S. DEA identified continued tours by the psychedelic rock band The Grateful Dead and the then-burgeoning rave scene as primary venues for LSD trafficking and consumption. American LSD usage fell sharply circa 2000, following one of the largest LSD manufacturing raids in DEA history, the arrest of two chemists, William Leonard Pickard and Clyde Apperson.<ref name=WLPickard>{{cite news
| author = Seper, Jerry.
| url =
| archiveurl =
| archivedate = 2007-01-30
| title = Man sentenced to life in prison as dealer of LSD
| publisher = The Washington Times
| date = 2003-11-27
| accessdate = 2008-02-01}}</ref>

== Notable Individuals ==
Many notable individuals have commented publicly on their experiences with LSD.<ref>{{cite web
|     title = Famous LSD users
|       url =
| publisher = The Good Drugs Guide
|accessdate = 2008-10-20
}}</ref> Some of these comments date from the era when it was legally available in the US and Europe for non-medical uses, and others pertain to psychiatric treatment in the 1950s and 60s. Still others describe experiences with illegal LSD, obtained for philosophic, artistic, therapeutic, spiritual, or recreational purposes.

== See also ==
*ALD-52, chemical analogue of LSD
*LSA, chemical analogue of LSD
*Methysergide, headache medication, chemically related to LSD
*Mind at Large
*Psychedelic experience
*The 60s
*United States v. Stanley, US Supreme Court case, compensation for secret military LSD experiments
*Urban legends about LSD

== References ==

== Further reading ==

* Bebergal, Peter, "Will Harvard drop acid again? Psychedelic research returns to Crimsonland", The Phoenix (Boston), June 2, 2008
* Grof, Stanislav. LSD Psychotherapy. (April 10, 2001)
* Lee, Martin A. and Bruce Shlain. Acid Dreams: The Complete Social History of LSD: The CIA, the Sixties, and Beyond (1992) ISBN 9780802130624
* Marks, John. The Search for the Manchurian Candidate: The CIA and Mind Control (1979), ISBN 0812907736
* Roberts, Andy. Albion Dreaming: A Popular History of LSD in Britain (2008), Marshall Cavendish,U.K, ISBN 1905736274
* Stevens, Jay. Storming Heaven: LSD And The American Dream (1998) ISBN 9780802135872
* Hofmann, Albert. LSD My Problem Child: Reflections on Sacred Drugs, Mysticism and Science (1983) ISBN 9780966001983
* Henderson, Leigh A. and William J. Glass. LSD: Still With Us After All These Years: Based on the National Institute of Drug Abuse Studies on the Resurgence of Contemporary LSD Use (1st edition 1994, 2nd edition 1998) ISBN 9780787943790
* de Rios, Marlene Dobkin and Oscar Janiger. LSD, spirituality, and the creative process (2003, Inner Traditions) ISBN 9780892819737 - "An exploration of how LSD influences imagination and the creative process. Based on the results of one of the longest clinical studies of LSD that took place between 1954 and 1962, before LSD was illegal. Includes personal reports, artwork, and poetry from the original sessions as testimony of the impact of LSD on the creative process."
* Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008 Winter;14(4):295-314. PMID 19040555

== External links ==
* Erowid Vaults: LSD-25
* The Lycaeum Archive: LSD
* TIHKAL entry for LSD-25
* WWW Psychedelic Bibliography, MAPS - large database of scientific publications on LSD and other psychedelics, fulltext PDFs  
* Current LSD Research – MAPS
* InfoFacts - Hallucinogens NIDA  
* Talk to Frank UK government anti-drug site on LSD
* Scholarly bibliography on the histories of LSD use
* My LSD Trip: a non-cop, non-hippie report of the unvarnished facts, by Robert Gannon, Popular Science Magazine, December 1967.
* LSD Returns--For Psychotherapeutics (Scientific American Magazine article)

== Documentaries ==
* Hofmann's Potion a documentary on the origins of LSD
* Power & Control LSD in The Sixties, documentary film directed by Aron Ranen, 2006<!-- This video was uploaded to YouTube by the director -->
* Inside LSD National Geographic Channel, 2009

Template:Drug use
Template:Hallucinogenic lysergamides

<!-- Metadata: see Wikipedia:InChI -->
|PIN=Lysergic acid diethylamide

Template:Link FA
ar:إل إس دي
cs:Diethylamid kyseliny lysergové
el:Διαιθυλαμίδιο του λυσεργικού οξέος
ko:리세르그산 디에틸아미드
hr:Lisergična dietilamidna kiselina
id:Asam lisergat dietilamida
lv:Lizergīnskābes dietilamīds
ms:Dietilamida asid lisergik
ja:LSD (薬物)
pl:Dietyloamid kwasu lizergowego
pt:Dietilamida do ácido lisérgico
ro:Acid lisergic dietilamid
simple:Lysergic acid diethylamide
sk:Dietylamid kyseliny lysergovej

Ad blocker interference detected!

Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.